[1] 尚晓倩,赵慧,马秀敏,等.microRNA与结核分枝杆菌感染的致病机制研究进展[J].中华医院感染学杂志,2019,29(3):477-480. SHANG X Q,ZHAO H,MA X M,et al.Research progress in microRNA and the pathogenesis of Mycobacterium tuberculosis infection[J].Chinese Journal of Nosocomiology,2019,29(3):477-480.(in Chinese) [2] 刘永安,李学瑞,刘永生.结核分枝杆菌耐药机制与检测技术研究进展[J].中国畜牧兽医,2017,44(6):1884-1889. LIU Y A,LI X R,LIU Y S.Research progress on resistance mechanisms and detecting technology of Mycobacterium tuberculosis[J].China Animal Husbandry & Veterinary Medicine,2017,44(6):1884-1889.(in Chinese) [3] SANTOS P,COSTA E,RAMALHO D,et al.Detection of tuberculosis drug resistance:A comparison by Mycobacterium tuberculosis mLPA assay versus genotype MtbDRplus[J].Memórias do Instituto Oswaldo Cruz,2017,112(6):396-403. [4] 陈淑艳.畜禽结核病的流行、临床诊断和防控[J].饲料博览,2017,5:62. CHEN S Y.Prevalence,clinical diagnosis,prevention and control of tuberculosis in livestock and poultry[J].Feed Review,2017,5:62.(in Chinese) [5] WHO.Global tuberculosis report 2016[R].Geneva World Health Organization,2016. [6] WHO.Global tuberculosis report 2017[R].Geneva World Health Organization,2017. [7] 曹志亮.结核分枝杆菌的耐药机制与治疗进展[J].医疗装备,2017,30(10):194-195. CAO Z L.Drug resistance mechanism and treatment progress of Mycobacterium tuberculosis[J].Medical Equipment,2017,30(10):194-195.(in Chinese) [8] 张志强,陈雅丽,高洁,等.2012-2017年陕西汉中市结核病实验室痰涂片镜检数据分析[J].实用预防医学,2019,26(2):149-152. ZHANG Z Q,CHEN Y L,GAO J,et al.Results of sputum smear microscopy in tuberculosis laboratories in Hanzhong city,Shaanxi,2012-2017[J].Practical Preventive Medicine,2019,26(2):149-152.(in Chinese) [9] 童叶青,侯双翼,叶建君,等.抗结核药物研究新进展[J].中国药师,2016,16(8):1236-1239. TONG Y Q,HOU S Y,YE J J,et al.New progress in anti-tuberculosis drugs[J].China Pharmacist,2016,16(8):1236-1239.(in Chinese) [10] 罗文武,刘姣,朱元东,等.重组卡介苗的应用研究及进展[J].山东畜牧兽医,2016,37(4):47-49. LUO W W,LIU J,ZHU Y D,et al.Application research and progress of recombinant BCG[J].Shandong Livestock Veterinary,2016,37(4):47-49.(in Chinese) [11] TANG J S,YAM W C,CHEN Z W.Mycobacterium tuberculosis infection and vaccine development[J].Tuberculosis,2016,98(5):30-41. [12] 罗文武.弓形虫Rhomboid基因重组卡介苗的构建及其对犬的免疫效果[D].长春:吉林大学,2015. LUO W W.Development of recombinant BCG of Toxoplasma gondii Rhomboid gene and its immune effect of canine[J].Changchun:Jilin University,2015.(in Chinese) [13] STOVER C K,CRUZ V F,FUERST T R,et al.New use of BCG for recombinant vaccines[J].Nature,1991,351(6326):456-460. [14] HORWITZ M A,HARTH G,DILLON B J,et al.Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model[J].Proceedings of the National Academy of Sciences of the United States of America,2000,97(25):13853-13858. [15] 姜德华.结核分枝杆菌融合蛋白疫苗(Ag85B-ESAT6)的构建及及免疫学特性的研究[D].长春:吉林大学,2010. JIANG D H.Construction and immunological characteristics of Mycobacterium tuberculosis fusion protein vaccine (Ag85B-ESAT6)[D].Changchun:Jilin University,2010.(in Chinese) [16] RAO M,NATHALIE C,MEG F,et al.Mycobacterium tuberculosis proteins involved in cell wall lipid biosynthesis improve BCG vaccine efficacy in a murine TB model[J].International Journal of Infectious Diseases,2017,56(1):274-282. [17] 吴植,郝福星,王永娟,等.特异性靶向犬细小病毒融合DNA疫苗的构建及免疫效果的研究[J].中国畜牧兽医,2016,43(10):2768-2774. WU Z,HAO F X,WANG Y J,et al.Construction of specifically targeted chimeric canine parvovirus DNA vaccine and its efficacy assessment[J].China Animal Husbandry & Veterinary Medicine,2016,43(10):2768-2774.(in Chinese) [18] MICHELLE H L,KAROLIN B,WILLIAM R J.Laboratory maintenance of Mycobacterium tuberculosis[J].Current Protocols in Microbiology,2007,10:1-8. [19] LUCA S,MIHAESCU T.History of BCG vaccine[J].Maedica,2013,8(1):53-58. [20] STERNE J A,RODRIGUES L C,GUEDES I N.Does the efficacy of BCG decline with time since vaccination[J].International Journal of Tuberculosis and Lung Disease,1998,2(3):200-207. |